The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) will face an 11.5% price cut in August under Japan’s quarterly price review, which basically triggers re-pricing for better-than-expected sales, Jiho learned. This brings down prices for three other I/O agents as well, slapping…
To read the full story
Related Article
- Imfinzi Faces Price Slash of 25%, Polivy 15% in February: Quarterly Re-Pricing
November 16, 2023
- Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
- Keytruda to Get 17.5% Price Cut in February
November 13, 2019
- Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
- Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
August 29, 2019
- Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
August 27, 2019
- Maviret Faces 25% Price Slash in Quarterly Review
November 14, 2018
- Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
REGULATORY
- OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
December 19, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
December 18, 2025
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…